Colorado PROFILES, The Colorado Clinical and Translational Sciences Institute (CCTSI)
Keywords
Last Name
Institution

Contact Us
If you have any questions or feedback please contact us.

Bradley Corr

Concepts (221)

Concepts are derived automatically from a person's publications.

Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.

Name Number of Publications Most Recent Publication Publications by All Authors Concept Score Why?
Endometrial Neoplasms
23
2026
205
6.980
Why?
Ovarian Neoplasms
14
2025
598
3.000
Why?
Neoplasm Recurrence, Local
10
2025
1156
2.300
Why?
beta Catenin
5
2025
250
2.040
Why?
Antineoplastic Combined Chemotherapy Protocols
14
2025
1996
1.810
Why?
Carcinoma, Endometrioid
3
2022
49
1.740
Why?
Poly(ADP-ribose) Polymerase Inhibitors
3
2025
137
1.630
Why?
Antibodies, Monoclonal, Humanized
8
2026
992
1.410
Why?
Phenylurea Compounds
4
2025
122
1.290
Why?
Quinolines
4
2025
191
1.250
Why?
Wnt Signaling Pathway
3
2025
211
0.910
Why?
Phthalazines
1
2025
63
0.880
Why?
Lymph Nodes
2
2018
511
0.830
Why?
Uterine Cervical Neoplasms
6
2024
269
0.790
Why?
Piperazines
1
2025
367
0.760
Why?
Indoles
1
2025
509
0.670
Why?
Wnt Proteins
1
2021
131
0.630
Why?
Aged, 80 and over
23
2025
8351
0.620
Why?
Mutation
6
2025
4082
0.590
Why?
Tumor Suppressor Protein p53
5
2025
530
0.590
Why?
Camptothecin
3
2025
139
0.580
Why?
Immunoconjugates
3
2025
138
0.570
Why?
Female
50
2026
79080
0.520
Why?
Drug Resistance, Neoplasm
7
2025
889
0.500
Why?
Adenocarcinoma, Mucinous
1
2018
76
0.500
Why?
Practice Patterns, Physicians'
2
2025
1370
0.490
Why?
Antineoplastic Agents
5
2025
2218
0.480
Why?
Middle Aged
34
2026
36359
0.480
Why?
Gynecologic Surgical Procedures
2
2020
67
0.470
Why?
Keratin-5
1
2015
43
0.450
Why?
Aged
29
2026
26251
0.440
Why?
Neoplasms, Glandular and Epithelial
1
2015
52
0.440
Why?
Venous Thromboembolism
2
2020
330
0.440
Why?
Cisplatin
2
2023
346
0.430
Why?
Hysterectomy
4
2019
138
0.420
Why?
Humans
54
2026
145625
0.390
Why?
Bile Ducts, Intrahepatic
1
2013
62
0.390
Why?
Neoplasm Grading
4
2025
313
0.370
Why?
Microsatellite Instability
2
2025
57
0.360
Why?
Cholangiocarcinoma
1
2013
110
0.360
Why?
Biomarkers, Tumor
6
2025
1334
0.360
Why?
Adult
28
2026
40821
0.350
Why?
Bile Duct Neoplasms
1
2013
132
0.350
Why?
Cell Line, Tumor
5
2025
3538
0.340
Why?
Genital Neoplasms, Female
3
2024
100
0.340
Why?
Lymph Node Excision
3
2018
173
0.340
Why?
Cerebral Palsy
2
2025
146
0.330
Why?
Molecular Targeted Therapy
2
2025
446
0.310
Why?
Gene Expression Regulation, Neoplastic
3
2025
1429
0.280
Why?
Maytansine
2
2025
18
0.270
Why?
Pyrimidinones
2
2025
124
0.250
Why?
Immunotherapy
3
2025
669
0.250
Why?
Bevacizumab
3
2025
167
0.250
Why?
MutL Protein Homolog 1
1
2026
11
0.240
Why?
Immunohistochemistry
2
2023
1709
0.230
Why?
Sensorimotor Cortex
1
2025
8
0.230
Why?
Homologous Recombination
1
2025
37
0.230
Why?
Maintenance Chemotherapy
1
2025
41
0.220
Why?
Cell Survival
2
2021
1102
0.220
Why?
CTLA-4 Antigen
1
2025
105
0.220
Why?
DNA Mismatch Repair
4
2026
54
0.220
Why?
Drug Synergism
1
2025
353
0.210
Why?
Folate Receptor 1
1
2024
17
0.210
Why?
Xenograft Model Antitumor Assays
2
2025
928
0.210
Why?
Uterine Neoplasms
1
2025
98
0.200
Why?
Cystadenocarcinoma, Serous
1
2025
90
0.200
Why?
Tryptophan Oxygenase
1
2024
33
0.200
Why?
Pyrazoles
3
2025
516
0.190
Why?
DNA Polymerase II
2
2023
35
0.190
Why?
Poly-ADP-Ribose Binding Proteins
2
2023
35
0.190
Why?
Exercise Therapy
2
2025
486
0.190
Why?
Gait
1
2025
316
0.180
Why?
Tertiary Care Centers
1
2023
194
0.180
Why?
Fallopian Tube Neoplasms
1
2022
19
0.180
Why?
Neoplasms
3
2022
2944
0.170
Why?
Thrombocytopenia
1
2023
205
0.170
Why?
Radiosurgery
1
2025
398
0.170
Why?
Heterocyclic Compounds, 3-Ring
1
2021
44
0.170
Why?
DNA Methylation
1
2026
721
0.160
Why?
Indazoles
1
2021
86
0.160
Why?
Disease Progression
3
2025
2857
0.160
Why?
Retrospective Studies
7
2025
17291
0.160
Why?
Precision Medicine
1
2025
462
0.160
Why?
Clinical Trials, Phase I as Topic
1
2020
49
0.160
Why?
Benzoxazoles
1
2020
20
0.160
Why?
Double-Blind Method
1
2025
2064
0.160
Why?
High-Throughput Nucleotide Sequencing
1
2023
538
0.150
Why?
Cohort Studies
5
2026
6045
0.150
Why?
Neoplasm Staging
3
2019
1486
0.150
Why?
Imidazoles
1
2021
244
0.150
Why?
Azepines
1
2020
104
0.150
Why?
Enoxaparin
1
2020
68
0.150
Why?
Mindfulness
1
2021
133
0.150
Why?
Disease Susceptibility
1
2021
339
0.150
Why?
Machine Learning
1
2025
590
0.140
Why?
Survival Analysis
3
2020
1372
0.140
Why?
Margins of Excision
1
2019
54
0.140
Why?
Class I Phosphatidylinositol 3-Kinases
1
2019
109
0.140
Why?
Pyridones
1
2020
210
0.140
Why?
Frozen Sections
1
2018
23
0.130
Why?
Recurrence
1
2021
1125
0.130
Why?
PTEN Phosphohydrolase
1
2019
166
0.130
Why?
Oncologists
1
2018
47
0.130
Why?
Protein Kinase Inhibitors
2
2023
982
0.130
Why?
Preoperative Care
2
2017
375
0.130
Why?
Postural Balance
1
2020
241
0.130
Why?
Cross-Sectional Studies
3
2018
5875
0.130
Why?
Colorectal Neoplasms
1
2025
870
0.130
Why?
Disease Management
1
2021
649
0.120
Why?
Pyridines
1
2021
606
0.120
Why?
Pyrimidines
1
2020
530
0.120
Why?
Minority Groups
1
2018
285
0.120
Why?
Amyotrophic Lateral Sclerosis
3
2003
98
0.120
Why?
Gynecology
1
2018
184
0.120
Why?
Tissue Array Analysis
1
2015
49
0.110
Why?
Perioperative Period
1
2015
69
0.110
Why?
Neoplasm Invasiveness
1
2017
503
0.110
Why?
Radiography, Thoracic
1
2016
174
0.110
Why?
Anticoagulants
1
2020
743
0.110
Why?
Laparotomy
1
2015
109
0.100
Why?
Heparin
1
2015
246
0.100
Why?
Surgeons
1
2018
337
0.100
Why?
Disease Models, Animal
1
2024
4565
0.100
Why?
Platinum
2
2025
48
0.100
Why?
Quality of Health Care
1
2018
692
0.100
Why?
Magnetoencephalography
2
2025
161
0.100
Why?
Treatment Outcome
3
2020
11744
0.090
Why?
Receptors, Estrogen
1
2015
405
0.090
Why?
Membrane Proteins
1
2019
1130
0.090
Why?
Paclitaxel
2
2025
258
0.090
Why?
Combined Modality Therapy
2
2013
1269
0.090
Why?
Robotic Surgical Procedures
1
2015
204
0.090
Why?
Ovary
1
2013
235
0.090
Why?
Case-Control Studies
1
2019
3633
0.080
Why?
Prognosis
5
2023
4331
0.080
Why?
Maximum Tolerated Dose
2
2022
216
0.080
Why?
Breast Neoplasms
1
2024
2411
0.080
Why?
Young Adult
6
2025
14240
0.080
Why?
Chemoradiotherapy
2
2025
238
0.080
Why?
Mice
2
2025
18266
0.080
Why?
Postoperative Complications
2
2020
2962
0.080
Why?
Prospective Studies
4
2023
8087
0.080
Why?
Tumor Microenvironment
2
2024
745
0.070
Why?
Cell Proliferation
1
2015
2497
0.070
Why?
Animals
3
2025
38030
0.070
Why?
Adolescent
6
2025
22451
0.060
Why?
Apoptosis
1
2015
2436
0.060
Why?
Germ-Line Mutation
1
2026
180
0.060
Why?
Genomic Instability
1
2025
64
0.050
Why?
Retreatment
1
2025
79
0.050
Why?
Neoplastic Syndromes, Hereditary
1
2025
47
0.050
Why?
GPI-Linked Proteins
1
2025
81
0.050
Why?
Carboplatin
1
2025
168
0.050
Why?
Carbonyl Reductase (NADPH)
1
2024
5
0.050
Why?
Wnt4 Protein
1
2024
19
0.050
Why?
Programmed Cell Death 1 Receptor
1
2025
268
0.050
Why?
Cell Adhesion Molecules
1
2024
180
0.050
Why?
Kynurenine
1
2024
114
0.050
Why?
Disease-Free Survival
1
2025
777
0.050
Why?
Mesylates
1
2022
7
0.050
Why?
Antigens, Neoplasm
1
2024
271
0.050
Why?
Topoisomerase I Inhibitors
1
2022
20
0.050
Why?
Tryptophan
1
2024
183
0.050
Why?
AMP-Activated Protein Kinases
1
2024
192
0.050
Why?
Lung Neoplasms
1
2016
2674
0.050
Why?
Registries
3
2018
2382
0.040
Why?
Ligands
1
2024
676
0.040
Why?
Somatosensory Cortex
1
2022
42
0.040
Why?
B7-H1 Antigen
1
2024
245
0.040
Why?
Promoter Regions, Genetic
1
2026
1236
0.040
Why?
Antibodies, Bispecific
1
2022
70
0.040
Why?
Ambulatory Care Facilities
1
2003
267
0.040
Why?
Quality of Life
2
2025
3187
0.040
Why?
Enzyme Inhibitors
1
2024
820
0.040
Why?
Decision Trees
1
2000
75
0.040
Why?
Aurora Kinase A
1
2020
57
0.040
Why?
Mechanistic Target of Rapamycin Complex 2
1
2020
62
0.040
Why?
Interleukin-6
1
2024
782
0.040
Why?
Vascular Endothelial Growth Factor A
1
2022
543
0.040
Why?
Mechanistic Target of Rapamycin Complex 1
1
2020
138
0.040
Why?
Physical Examination
1
2020
236
0.040
Why?
Randomized Controlled Trials as Topic
1
2025
1754
0.030
Why?
Adenine
1
2020
338
0.030
Why?
Neoplasm Metastasis
1
2020
693
0.030
Why?
Patient Care Team
1
2003
700
0.030
Why?
Ireland
3
2003
33
0.030
Why?
Program Evaluation
1
2021
945
0.030
Why?
Walking
1
2022
544
0.030
Why?
Physical Therapy Modalities
1
2020
341
0.030
Why?
Regression Analysis
1
2019
994
0.030
Why?
Macrophages
1
2024
1530
0.030
Why?
Brain Neoplasms
1
2025
1324
0.030
Why?
RNA
1
2022
925
0.030
Why?
Neoadjuvant Therapy
1
2018
474
0.030
Why?
Ileus
1
2015
13
0.030
Why?
Salpingectomy
1
2015
15
0.030
Why?
Urinary Retention
1
2015
23
0.030
Why?
Ovariectomy
1
2015
164
0.030
Why?
Blood Loss, Surgical
1
2015
116
0.030
Why?
Survival Rate
1
2019
2078
0.030
Why?
Pelvis
1
2015
129
0.020
Why?
Logistic Models
1
2018
2112
0.020
Why?
Pandemics
1
2021
1700
0.020
Why?
Caregivers
1
2021
1079
0.020
Why?
Patient Readmission
1
2018
771
0.020
Why?
Follow-Up Studies
2
2018
5397
0.020
Why?
Referral and Consultation
1
2018
878
0.020
Why?
United States
2
2019
16041
0.020
Why?
Signal Transduction
1
2024
5234
0.020
Why?
Male
5
2025
73014
0.020
Why?
Length of Stay
1
2015
1342
0.020
Why?
Immunotherapy, Adoptive
1
2012
356
0.020
Why?
Patient Discharge
1
2015
991
0.020
Why?
Diagnosis, Differential
2
2003
1500
0.020
Why?
Age Factors
1
2015
3321
0.020
Why?
Antibodies, Monoclonal
1
2012
1511
0.010
Why?
Interprofessional Relations
1
2003
274
0.010
Why?
Child
1
2020
22638
0.010
Why?
Central Nervous System Diseases
1
2000
73
0.010
Why?
Age of Onset
1
2000
557
0.010
Why?
Palliative Care
1
2003
1032
0.010
Why?
Corr's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts Expand Description
_
Co-Authors Expand Description
_
Similar People Expand Description
_
Same Department Expand Description
Physical Neighbors Expand Description
_

Copyright © 2026 The Regents of the University of Colorado, a body corporate. All rights reserved. (Harvard PROFILES RNS software version: 2.11.1)